CTIM-24. PHASE II TRIAL OF RHIL-7-HYFC IN PATIENTS WITH HIGH-GRADE GLIOMA DEMONSTRATED ACCEPTABLE SAFETY PROFILE AND REDUCED LYMPHOPENIA von Derek Li, Yuping, Luo, Jingqin Rosy, Grote, Cierra, Nehring, Leslie, Katumba, Ruth, Etter, Kelsey, Barozinsky, Kaiden, Ferrando-Martinez, Sara, Stermer, Kristina, Lee, Byung Ha, Johanns, Tanner, Butt, Omar, Huang, Jiayi, Campian, Jian L, Chheda, Milan G

Volltext

CTIM-30. NT-I7, A LONG-ACTING INTERLEUKIN-7, PROMOTES ACTIVATION, CYTOTOXIC FUNCTION, AND SELECTIVE CLONOTYPE EXPANSION OF CD8+ T CELLS IN PATIENTS WITH HIGH GRADE GLIOMAS von Barozinsky, Kaiden, Foltz, Jennifer A, Butt, Omar H, Zhou, Alice Y, Singhal, Kartik, Griffith, Obi, Griffith, Malachi, Etter, Kelsey, Grote, Cierra, Luo, Jingqin, Nehring, Leslie, Katumba, Ruth, Ferrando-Martinez, Sara, Stermer, Kristina, Lee, Byung Ha, Johanns, Tanner, Huang, Jiayi, DiPersio, John, Chheda, Milan, Fehniger, Todd, Campian, Jian L

Volltext